Longitudinal association of obesity, metabolic syndrome and diabetes with risk of elevated aminotransferase levels in a cohort of Mexican health workers

Journal of Digestive Diseases

Volumn 17, Issue 5, 2016, Pages 304-312

  Flores, Yvonne N ^a,b   Auslander, Allyn ^b   Crespi, Catherine M ^b   Rodriguez, Michael ^c   Zhang, Zuo Feng ^b   Durazo, Francisco ^c   Salmerón, Jorge ^a,d  

^a INSTITUTO MEXICANO DEL SEGURO SOCIAL   (Mexico)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d INSTITUTO NACIONAL DE SALUD PÚBLICA   (Mexico)

Author keywords

diabetes; liver diseases; metabolic syndrome; Mexico; obesity

Indexed keywords

ALANINE AMINOTRANSFERASE;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALCOHOL CONSUMPTION; ARTICLE; BINGE DRINKING; BODY MASS; COHORT ANALYSIS; CROSS-SECTIONAL STUDY; DIABETES MELLITUS; DISEASE ASSOCIATION; FEMALE; HEALTH CARE PERSONNEL; HUMAN; LIVER INJURY; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; MEXICO; OBESITY; PREVALENCE; PRIORITY JOURNAL; RISK FACTOR; WEIGHT GAIN;

EID: 84978811074     PISSN: 17512972     EISSN: 17512980     Source Type: Journal    
DOI: 10.1111/1751-2980.12341     Document Type: Article

References (53)

1. Rivera JA, Barquera S, González-Cossío T, Olaiz G, Sepúlveda J. Nutrition transition in Mexico and in other Latin American countries. Nutr Rev 2004; 62: S149–57.
2. Frenk J, Frejka T, Bobadilla JL et al. The epidemiologic transition in Latin America. Bol Oficina Sanit Panam 1991; 111: 485–96 (in Spanish).
3. Instituto Nacional de Estadística y Geografía. Mujeres y hombres en México 2013. Cited: 22 March 2016. Available from URL: http://www.inegi.org.mx/prod_serv/contenidos/espanol/bvinegi/productos/integracion/sociodemografico/mujeresyhombres/2013/Myh_2013.pdf (in Spanish).
4. Sistema Nacional de Información en Salud (2011). Principales causas de mortalidad en edad productiva (de 15 a 64 años), 2008. Cited: 22 March 2016. Available from URL: http://www.dgis.salud.gob.mx/contenidos/sinais/e_mortalidadgeneral.html (in Spanish).
5. Méndez-Sánchez N, Villa AR, Chávez-Tapia NC et al. Trends in liver disease prevalence in Mexico from 2005 to 2050 through mortality data. Ann Hepatol 2005; 4: 52–5.
6. Williams R. Global challenges in liver disease. Hepatology 2006; 44: 521–6.
7. World Health Organization. Hepatitis. (2013). Cited: 22 March 2016. Available from URL: http://www.who.int/immunization/topics/hepatitis/en/
8. Rehm J, Samokhvalov AV, Shield KD. Global burden of alcoholic liver diseases. J Hepatol 2013; 59: 160–8.
9. Zheng RD, Chen ZR, Chen JN, Lu YH, Chen J. Role of body mass index, waist-to-height and waist-to-hip ratio in prediction of nonalcoholic fatty liver disease. Gastroenterol Res Pract 2012; 2012: 362147.
10. Regimbeau JM, Colombat M, Mognol P et al. Obesity and diabetes as a risk factor for hepatocellular carcinoma. Liver Transpl 2004; 10 (2 Suppl 1): S69–73.
11. Watanabe S, Yaginuma R, Ikejima K, Miyazaki A. Liver diseases and metabolic syndrome. J Gastroenterol 2008; 43: 509–18.
12. Smits MM, Ioannou GN, Boyko EJ, Utzschneider KM. Non-alcoholic fatty liver disease as an independent manifestation of the metabolic syndrome: Results of a US national survey in three ethnic groups. J Gastroenterol Hepatol 2013; 28: 664–70.
13. Firneisz G. Non-alcoholic fatty liver disease and type 2 diabetes mellitus: the liver disease of our age? World J Gastroenterol 2014; 20: 9072–89.
14. Davila JA, Morgan RO, Shaib Y, McGlynn KA, El-Serag HB. Diabetes increases the risk of hepatocellular carcinoma in the United States: a population based case control study. Gut 2005; 54: 533–9.
15. Ascha MS, Hanouneh IA, Lopez R, Tamini TA, Feldstein AF, Zein NN. The incidence and risk factors of hepatocellular carcinoma in patients with nonalcoholic steatohepatitis. Hepatology 2010; 51: 1972–8.
16. Clark JM. The epidemiology of nonalcoholic fatty liver disease in adults. J Clin Gastroenterol 2006; 40 Suppl 1: S5–10.
17. Rtveladze K, Marsh T, Barquera S et al. Obesity prevalence in Mexico: impact on health and economic burden. Public Health Nutr 2014; 17: 233–9.
18. Rojas R, Aguilar-Salinas CA, Jiménez-Corona A et al. Metabolic syndrome in Mexican adults: results from the National Health and Nutrition Survey 2006. Salud Publica Mex 2010; 52 Suppl 1: S11–8.
19. González-Villalpando C, Dávila-Cervantes C, Zamora-Macorra M, Trejo-Valdivia B, González-Villalpando ME. Incidence of type 2 diabetes in Mexico: results of the Mexico City Diabetes Study after 18 years of follow-up. Salud Publica Mex 2014; 56: 11–7.
20. Pratt DS, Kaplan MM. Evaluation of abnormal liver-enzyme results in asymptomatic patients. N Engl J Med 2000; 342: 1266–71.
21. Spradling PR, Bulkow L, Teshale EH et al. Prevalence and causes of elevated serum aminotransferase levels in a population-based cohort of persons with chronic hepatitis B virus infection. J Hepatol 2014; 61: 785–91.
22. Pendino GM, Mariano A, Surace P et al. Prevalence and etiology of altered liver tests: a population-based survey in a Mediterranean town. Hepatology 2005; 41: 1151–9.
23. Kim WR, Flamm SL, Di Bisceglie AM, Bodenheimer HC; Public Policy Committee of the American Association for the Study of Liver Disease. Serum activity of alanine aminotransferase (ALT) as an indicator of health and disease. Hepatology 2008; 47: 1363–70.
24. Ruhl CE, Everhart JE. Determinants of the association of overweight with elevated serum alanine aminotransferase activity in the United States. Gastroenterology 2003; 124: 71–9.
25. Clark JM, Brancati FL, Diehl AM. The prevalence and etiology of elevated aminotransferase levels in the United States. Am J Gastroenterol 2003; 98: 960–7.
26. Flores YN, Yee HF Jr, Leng M et al. Risk factors for chronic liver disease in Blacks, Mexican Americans, and Whites in the United States: results from NHANES IV, 1999–2004. Am J Gastroenterol 2008; 103: 2231–8.
27. Park SH, Jeon WK, Kim SH et al. Prevalence and risk factors of non-alcoholic fatty liver disease among Korean adults. J Gastroenterol Hepatol 2006; 21: 138–43.
28. Dassanayake AS, Kasturiratne A, Rajindrajith S et al. Prevalence and risk factors for non-alcoholic fatty liver disease among adults in an urban Sri Lankan population. J Gastroenterol Hepatol 2009; 24: 1284–8.
29. Dam Fialla A, Schaffalitzky de Muckadell OB, Touborg Lassen A. Incidence, etiology and mortality of cirrhosis: a population-based cohort study. Scand J Gastroenterol 2012; 47: 702–9.
30. N'Kontchou G, Paries J, Htar MT et al. Risk factors for hepatocellular carcinoma in patients with alcoholic or viral C cirrhosis. Clin Gastroenterol Hepatol 2006; 4: 1062–8.
31. Wang CS, Yao WJ, Chang TT, Wang ST, Chou P. The impact of type 2 diabetes on the development of hepatocellular carcinoma in different viral hepatitis statuses. Cancer Epidemiol Biomarkers Prev 2009; 18: 2054–60.
32. Villegas R, Xiang YB, Elasy T et al. Liver enzymes, type 2 diabetes, and metabolic syndrome in middle-aged, urban Chinese men. Metab Syndr Relat Disord 2011; 9: 305–11.
33. Denova-Gutiérrez E, Huitrón-Bravo G, Talavera JO et al. Dietary glycemic index, dietary glycemic load, blood lipids, and coronary heart disease. J Nutr Metab 2010; 2010: 170680.
34. Méndez-Hernández P, Flores Y, Siani C et al. Physical activity and risk of metabolic syndrome in an urban Mexican cohort. BMC Public Health 2009; 9: 276.
35. Morales LS, Flores YN, Leng M, Sportiche N, Gallegos-Carrillo K, Salmerón J. Risk factors for cardiovascular disease among Mexican-American adults in the United States and Mexico: a comparative study. Salud Publica Mex 2014; 56: 197–205.
36. US Department of Health and Human Services. Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults. Washington, DC: US Department of Health and Human Services, 1998. Cited 22 March 2016. Available from URL: http://www.nhlbi.nih.gov/files/docs/guidelines/ob_gdlns.pdf
37. American Diabetes Association. Screening for type 2 diabetes. Diabetes Care 2004; 27 Suppl 1: S11–4.
38. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001; 285: 2486–97.
39. Jiles R, Hughes E, Murphy W et al. Surveillance for certain health behaviors among states and selected local areas---- Behavioral risk factor surveillance system, United States, 2003. MMWR Surveil Summ 2005; 54: 1–116.
40. Ioannou G, Boyko EJ, Lee SP. The prevalence and predictors of elevated serum aminotransferase activity in the United States in 1999–2002. Am J Gastroenterol 2006; 101: 76–82.
41. Bergmeyer HU, Hørder M, Rej R. International Federation of Clinical Chemistry (IFCC) Scientific Committee, Analytical Section: approved recommendation (1985) on IFCC methods for the measurement of catalytic concentration of enzymes. Part 3. IFCC method for alanine aminotransferase (L-alanine: 2-oxoglutarate aminotransferase, EC 2.6.1.2). J Clin Chem Clin Biochem 1986; 24: 481–95.
42. Gella F, Olivella T, Cruz Pastor M et al. A simple procedure for the routine determination of aspartate aminotransferase and alanine aminotransferase with pyridoxal phosphate. Clin Chim Acta 1985; 153: 241–7.
43. Statacorp. Stata Statistical Software: Release 12. College Station, TX: StataCorp LP, 2011.
44. Goessling W, Massaro JM, Vasan RS, D'Agostino RB Sr, Ellison RC, Fox CS. Aminotransferase levels and 20-year risk of metabolic syndrome, diabetes, and cardiovascular disease. Gastreoenterology 2008; 135: 1935–44.e1.
45. Tsai J, Ford ES, Li C, Zhao G. Past and current alcohol consumption patterns and elevations in serum hepatic enzymes among US adults. Addict Behav 2012; 37: 78–84.
46. Pan JJ, Qu HQ, Rentfro A, McCormick JB, Fisher-Hoch SP, Fallon MB. Prevalence of metabolic syndrome and risks of abnormal serum alanine aminotransferase in Hispanics: a population-based study. PLoS One 2011; 6: e21515.
47. Larrieta-Carrasco E, Acuña-Alonzo V, Velázquez-Cruz R et al. PNPLA3 I148M polymorphism is associated with elevated alanine transaminase levels in Mexican Indigenous and Mestizo populations. Mol Biol Rep 2014; 41: 4705–11.
48. Qu HQ, Li Q, Grove ML et al. Population-based risk factors for elevated alanine aminotransferase in a south Texas Mexican-American population. Arch Med Res 2012; 43: 482–8.
49. Kunutsor SK, Apekey TA, Walley J. Liver aminotransferases and risk of incident type 2 diabetes: a systematic review and meta-analysis. Am J Epidemiol 2013; 178: 159–71.
50. Secretaría de Economía Programa Nacional de Protección a los Derechos del Consumidor 2013-2018. Diario Oficial de la Federación. 2014. Cited 22 March 2016. Available from URL: http://dof.gob.mx/nota_detalle.php?codigo=5343849&fecha=08/05/2014 (in Spanish).
51. Lazo M, Hernaez R, Eberhardt MS et al. Prevalence of nonalcoholic fatty liver disease in the United States: the Third National Health and Nutrition Examination Survey, 1988–1994. Am J Epidemiol 2013; 178: 38–45.
52. Younossi ZM, Stepanova M. Hepatitis C virus infection, age, and Hispanic ethnicity increase mortality from liver cancer in the United States. Clin Gastroenterol Hepatol 2010; 8: 718–23.
53. Vega WA, Rodriguez MA, Gruskin E. Health disparities in the Latino population. Epidemiol Rev 2009; 31: 99–112.